CL2019000882A1 - Sustituto de 1h-imidazo[4,5-b]piridina-2(3h)-ones y sus uso como moduladores de receptor glun2b. - Google Patents
Sustituto de 1h-imidazo[4,5-b]piridina-2(3h)-ones y sus uso como moduladores de receptor glun2b.Info
- Publication number
- CL2019000882A1 CL2019000882A1 CL2019000882A CL2019000882A CL2019000882A1 CL 2019000882 A1 CL2019000882 A1 CL 2019000882A1 CL 2019000882 A CL2019000882 A CL 2019000882A CL 2019000882 A CL2019000882 A CL 2019000882A CL 2019000882 A1 CL2019000882 A1 CL 2019000882A1
- Authority
- CL
- Chile
- Prior art keywords
- imidazo
- pyridine
- substitute
- ones
- receptor modulators
- Prior art date
Links
- PGDIPOWQYRAOSK-UHFFFAOYSA-N 1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical class C1=CN=C2NC(=O)NC2=C1 PGDIPOWQYRAOSK-UHFFFAOYSA-N 0.000 title 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 title 1
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 3
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404798P | 2016-10-06 | 2016-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000882A1 true CL2019000882A1 (es) | 2019-06-21 |
Family
ID=61831306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000882A CL2019000882A1 (es) | 2016-10-06 | 2019-04-02 | Sustituto de 1h-imidazo[4,5-b]piridina-2(3h)-ones y sus uso como moduladores de receptor glun2b. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10617676B2 (enExample) |
| EP (1) | EP3523311B1 (enExample) |
| JP (1) | JP7001682B2 (enExample) |
| KR (1) | KR20190056435A (enExample) |
| CN (2) | CN110062761B (enExample) |
| AR (1) | AR109810A1 (enExample) |
| AU (1) | AU2017340602A1 (enExample) |
| BR (1) | BR112019006691A2 (enExample) |
| CA (1) | CA3038820A1 (enExample) |
| CL (1) | CL2019000882A1 (enExample) |
| EA (1) | EA201990848A1 (enExample) |
| ES (1) | ES2950881T3 (enExample) |
| IL (1) | IL265757A (enExample) |
| MA (1) | MA46470A (enExample) |
| MX (1) | MX2019003980A (enExample) |
| PH (1) | PH12019500676A1 (enExample) |
| TW (1) | TW201819376A (enExample) |
| WO (1) | WO2018067786A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3180329T3 (pl) | 2014-08-15 | 2020-08-24 | Janssen Pharmaceuticals, Inc. | Triazole jako inhibitory receptora NR2B |
| DK3180315T3 (da) | 2014-08-15 | 2020-04-06 | Janssen Pharmaceuticals Inc | Pyrazoler |
| AU2016291158B2 (en) | 2015-07-09 | 2020-04-30 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| WO2018098491A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11629146B2 (en) | 2016-11-28 | 2023-04-18 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity |
| WO2018148745A1 (en) * | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| MA52244A (fr) | 2018-04-04 | 2021-02-17 | Janssen Pharmaceutica Nv | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
| IL309843A (en) | 2018-05-30 | 2024-02-01 | Praxis Prec Medicines Inc | ion channel modulators |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| CN109499614B (zh) * | 2018-12-12 | 2021-06-04 | 怀化学院 | MOPs负载双齿螯合型金属催化剂及其制备方法 |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| JP2022538774A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | ピリジンカルバメート及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 |
| PE20220806A1 (es) | 2019-06-14 | 2022-05-20 | Janssen Pharmaceutica Nv | Pirazolo piridinas heteroaromaticas sustituidas y su uso como moduladores del receptor glun2b |
| EP3983413A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
| KR20220020917A (ko) * | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로[4,3-b]피리딘 및 GLUN2B 수용체 조절제로서의 이들의 용도 |
| KR20220020915A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도 |
| TW202112774A (zh) | 2019-06-14 | 2021-04-01 | 比利時商健生藥品公司 | 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途 |
| PH12021552839A1 (en) | 2019-06-14 | 2022-10-03 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| JP7526804B2 (ja) * | 2020-03-11 | 2024-08-01 | エニジェン カンパニー リミテッド | 新規化合物を含む抗糖尿病及び抗肥満用組成物 |
| EP4153575A4 (en) * | 2020-05-21 | 2024-07-17 | StemSynergy Therapeutics, Inc. | Notch inhibitors and uses thereof |
| CN112939986B (zh) * | 2021-02-18 | 2023-06-13 | 新乡医学院 | 一种吡唑并嘧啶类化合物的合成方法 |
| KR20230037391A (ko) * | 2021-09-09 | 2023-03-16 | 애니젠 주식회사 | 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| WO2025224308A1 (en) * | 2024-04-25 | 2025-10-30 | Scenic Immunology B.V. | Qpctl inhibitors |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
| CA2262502C (en) | 1996-07-31 | 2002-11-26 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same |
| JP2004501901A (ja) * | 2000-06-26 | 2004-01-22 | メルク エンド カムパニー インコーポレーテッド | イミノピリミジン系ｎｍｄａｎｒ２ｂ受容体拮抗薬 |
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| CN100368411C (zh) | 2002-03-28 | 2008-02-13 | 卫材R&D管理有限公司 | 作为c-Jun N-末端激酶抑制剂用于治疗神经变性疾病的7-氮杂吲哚类化合物 |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| JP4414881B2 (ja) * | 2002-05-31 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾール化合物およびこれを含んでなる医薬組成物 |
| EP1720860A1 (en) | 2004-02-18 | 2006-11-15 | AstraZeneca AB | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| AU2005286592A1 (en) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| RU2479577C2 (ru) | 2007-05-25 | 2013-04-20 | Эбботт Гмбх Унд Ко.Кг | Гетероциклические соединения в качестве положительных модуляторов метаботропного глутаматного рецептора 2 (рецептора mglu2) |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| CL2008002521A1 (es) | 2007-08-30 | 2009-11-20 | Takeda Pharmaceuticals Co | Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer. |
| WO2009058261A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | Modulation of sleep with nr2b receptor antagonists |
| EP2254580A1 (en) | 2008-03-27 | 2010-12-01 | EVOTEC Neurosciences GmbH | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| WO2009157196A1 (ja) | 2008-06-25 | 2009-12-30 | 武田薬品工業株式会社 | アミド化合物 |
| PT2308877E (pt) | 2008-08-05 | 2014-05-02 | Daiichi Sankyo Co Ltd | Derivados de imidazopiridin-2-ona |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| JP5656848B2 (ja) | 2008-10-16 | 2015-01-21 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体 |
| AU2009324894B2 (en) * | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
| EP2408753A4 (en) | 2009-03-20 | 2012-11-07 | Univ Brandeis | COMPOUNDS AND METHOD FOR THE TREATMENT OF MICROBIAL STOMACH DARM INFECTIONS IN MAMMALS |
| EP2579717A4 (en) * | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| JP2012188363A (ja) * | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| WO2013060029A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Allosteric modulators of metabotropic glutamate receptors |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| MX2015012432A (es) | 2013-03-13 | 2016-02-05 | Abbvie Inc | Inhibidores piridinicos de la cinasa cdk9. |
| SMT201800650T1 (it) | 2013-03-15 | 2019-01-11 | Plexxikon Inc | Composti eterociclici e loro impiego |
| KR102307566B1 (ko) * | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| SG11201600159TA (en) | 2013-07-31 | 2016-02-26 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
| AU2015296893A1 (en) | 2014-07-28 | 2017-02-02 | Safemate Australia Pty Ltd | Systems and methods for making personal emergency information available to third parties |
| PL3180329T3 (pl) | 2014-08-15 | 2020-08-24 | Janssen Pharmaceuticals, Inc. | Triazole jako inhibitory receptora NR2B |
| DK3180315T3 (da) | 2014-08-15 | 2020-04-06 | Janssen Pharmaceuticals Inc | Pyrazoler |
| US12006328B2 (en) * | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
| MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
| AU2016291158B2 (en) | 2015-07-09 | 2020-04-30 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| KR102892521B1 (ko) | 2017-06-14 | 2025-11-27 | 트레베나, 인코포레이티드. | S1p1 활성을 조정하기 위한 화합물 및 그를 사용하는 방법 |
| MA52244A (fr) | 2018-04-04 | 2021-02-17 | Janssen Pharmaceutica Nv | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
| CN110294756A (zh) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
| EP3983413A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
| PE20220806A1 (es) | 2019-06-14 | 2022-05-20 | Janssen Pharmaceutica Nv | Pirazolo piridinas heteroaromaticas sustituidas y su uso como moduladores del receptor glun2b |
| JP2022538774A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | ピリジンカルバメート及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 |
| KR20220020917A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로[4,3-b]피리딘 및 GLUN2B 수용체 조절제로서의 이들의 용도 |
| TW202112774A (zh) | 2019-06-14 | 2021-04-01 | 比利時商健生藥品公司 | 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途 |
| KR20220020915A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도 |
-
2017
- 2017-10-03 TW TW106134127A patent/TW201819376A/zh unknown
- 2017-10-05 AR ARP170102779A patent/AR109810A1/es unknown
- 2017-10-05 ES ES17859165T patent/ES2950881T3/es active Active
- 2017-10-05 MX MX2019003980A patent/MX2019003980A/es unknown
- 2017-10-05 CN CN201780075930.5A patent/CN110062761B/zh active Active
- 2017-10-05 AU AU2017340602A patent/AU2017340602A1/en not_active Abandoned
- 2017-10-05 BR BR112019006691A patent/BR112019006691A2/pt not_active Application Discontinuation
- 2017-10-05 CA CA3038820A patent/CA3038820A1/en active Pending
- 2017-10-05 JP JP2019518219A patent/JP7001682B2/ja active Active
- 2017-10-05 EP EP17859165.7A patent/EP3523311B1/en active Active
- 2017-10-05 KR KR1020197012678A patent/KR20190056435A/ko not_active Withdrawn
- 2017-10-05 MA MA046470A patent/MA46470A/fr unknown
- 2017-10-05 EA EA201990848A patent/EA201990848A1/ru unknown
- 2017-10-05 US US15/725,500 patent/US10617676B2/en active Active
- 2017-10-05 WO PCT/US2017/055278 patent/WO2018067786A1/en not_active Ceased
- 2017-10-05 CN CN202210460371.2A patent/CN114989164B/zh active Active
-
2019
- 2019-03-28 PH PH12019500676A patent/PH12019500676A1/en unknown
- 2019-04-01 IL IL265757A patent/IL265757A/en unknown
- 2019-04-02 CL CL2019000882A patent/CL2019000882A1/es unknown
-
2020
- 2020-03-03 US US16/807,385 patent/US11207298B2/en active Active
-
2021
- 2021-09-14 US US17/474,631 patent/US11759455B2/en active Active
-
2023
- 2023-06-29 US US18/344,169 patent/US20230338341A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10617676B2 (en) | 2020-04-14 |
| US20230000833A1 (en) | 2023-01-05 |
| PH12019500676A1 (en) | 2019-12-02 |
| CN110062761B (zh) | 2022-05-13 |
| EP3523311A1 (en) | 2019-08-14 |
| KR20190056435A (ko) | 2019-05-24 |
| EP3523311A4 (en) | 2020-03-18 |
| CA3038820A1 (en) | 2018-04-12 |
| EP3523311C0 (en) | 2023-06-07 |
| ES2950881T3 (es) | 2023-10-16 |
| IL265757A (en) | 2019-06-30 |
| US20180125826A1 (en) | 2018-05-10 |
| EA201990848A1 (ru) | 2019-08-30 |
| WO2018067786A1 (en) | 2018-04-12 |
| CN114989164A (zh) | 2022-09-02 |
| AR109810A1 (es) | 2019-01-23 |
| JP7001682B2 (ja) | 2022-01-19 |
| CN114989164B (zh) | 2024-08-13 |
| TW201819376A (zh) | 2018-06-01 |
| BR112019006691A2 (pt) | 2019-06-25 |
| US20210069155A1 (en) | 2021-03-11 |
| US20230338341A1 (en) | 2023-10-26 |
| CN110062761A (zh) | 2019-07-26 |
| US11207298B2 (en) | 2021-12-28 |
| MX2019003980A (es) | 2019-06-10 |
| JP2019530695A (ja) | 2019-10-24 |
| AU2017340602A1 (en) | 2019-04-18 |
| MA46470A (fr) | 2019-08-14 |
| US11759455B2 (en) | 2023-09-19 |
| EP3523311B1 (en) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019000882A1 (es) | Sustituto de 1h-imidazo[4,5-b]piridina-2(3h)-ones y sus uso como moduladores de receptor glun2b. | |
| CO2021016860A2 (es) | Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b | |
| CL2016001983A1 (es) | Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4 | |
| MX386752B (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
| CL2016001895A1 (es) | Compuestos | |
| ECSP21090478A (es) | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b | |
| MX381313B (es) | Derivados de benzimidazol como moduladores de ror-gamma | |
| CL2016002836A1 (es) | Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame). | |
| MX380777B (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| MX2016012021A (es) | Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| EA033281B1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
| CL2018001085A1 (es) | Derivados de indolin-2-ona | |
| BR112017001726A2 (pt) | compostos de 6,7-di-hidropirazolo [1,5-a]pirazin-4(5h)-ona e seus usos como moduladores alostéricos negativos de receptores mglur2 | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| GT201500243A (es) | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina | |
| WO2019193516A3 (en) | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| MX372781B (es) | Ciclopentanos 1,2-sustituidos como antagonistas del receptor de la orexina. | |
| CL2016000387A1 (es) | Derivados de amida como antagonistas de ácido receptor lisofosfatidico | |
| BR112017001861A2 (pt) | compostos de 6,7-di-hidropirazolo [1,5-a]pirazin-4(5h)-ona e seus usos como moduladores alostéricos negativos de receptores mglur2 | |
| MY201535A (en) | Therapeutic compounds | |
| CL2015003196A1 (es) | Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2. | |
| TW201613884A (en) | Selective NR2B antagonists |